Online, United States
Lectures & Conferences
The 6th PREDiCT: 3D Tissue Models Summit is the only industry-led summit focusing on real-world application of 3D models in drug discovery and development. With 25+ experts sharing fresh case studies on 3D Tissue Models data, how to foster technology maturation, and lower costs to drive industrial adoption, this is a conversation not to miss.
Our 2021 program will delve further into advanced 3D organoids, organ-on-chips, microphysiological systems (MPS), and tissue engineering - from oncology to other therapeutic areas such as neurodegenerative, respiratory, fibrosis, and the cardiovascular fields. Explore preclinical safety and toxicology models and translation in clinical Ph1 for biomarkers and patient stratification for better Ph2 design.
Join over 120+ senior leaders including Pfizer, Takeda, GSK, Roche, and FDA in September, to re-engage in the dialogue and discuss journeys and lessons learned with complex in vitro models, compared with conventional in vivo and 2D cell studies.
Drug Developers: Conference Only: USD 1999.0,
Academic: Conference Only: USD 1599.0,
Service Providers: Conference Only: USD 3199.0
Speakers: Madhu Lal-Nag, FDA, Matthew Wagoner, Takeda, Don Ingber, Wyss Institute for Biologically Inspired Engineering, Jason Ekert, Senior Director and Head of Complex In Vitro Models GSK, Jason Ekert, GSK, Roger Kamm, MIT, Danilo Tagle, NIH/ NCATS, Matthew Lech, Pfizer, Nicholas Geisse, Curi Bio, Shamin Li, Roche Diagnostics, Kimberly Homan, Genentech, Phillip Hewitt, Merck KGaA, Stephen Kasper, Merck and Co., Matthias Von Herrath, Novo Nordisk, BanuPriya Sridharan, GSK, Serah Kang, Genentech, Ruitao Su, University of Minnesota, Trivia Frazier, Obatala Sciences, Prathap Kumar, Abbvie, Madhuri Dey, Pennsylvania State University, Jos Joore, MIMETAS, Kristin Fabre, Baylor College, Jeroen Pouwels, University of Helsinki, Timothy Spicer, The Scripps Research Institute, Lisa Wagar, University of California Irvine, Annie Moisan, Wellcome Leap, Suwan N. Jayasinghe, UCL, Thomas Hartung, John Hopkins Bloomberg School of Public Health